A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Onartuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 04 Nov 2016 Status changed from recruiting to completed.
- 15 Jan 2014 New trial record